GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » Other Income (Expense)

Scandion Oncology A/S (OSTO:SCOL) Other Income (Expense) : kr1.49 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology A/S Other Income (Expense)?

Scandion Oncology A/S's other income expense for the Scandion Oncology A/S's pretax income for the three months ended in Mar. 2024 was kr-0.00 Mil. Its other income expense for the trailing twelve months (TTM) ended in Mar. 2024 was kr1.49 Mil.

Scandion Oncology A/S Other Income (Expense) Historical Data

The historical data trend for Scandion Oncology A/S's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology A/S Other Income (Expense) Chart

Scandion Oncology A/S Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial - -0.08 -1.49 -2.28 1.49

Scandion Oncology A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 1.49 -

Scandion Oncology A/S Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scandion Oncology A/S  (OSTO:SCOL) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Scandion Oncology A/S (OSTO:SCOL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » Other Income (Expense)
Comparable Companies
OSTO:EXPRS2 OSTO:COMBI XSAT:ABERA OSTO:LPGO NGM:COEGIN XSAT:CHOSA OSTO:2CUREX OSTO:BIOSGN XSAT:APTA XSAT:DBP B OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
8VY:Germany
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Website
https://www.scandiononcology.com
Scandion Oncology A/S is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology A/S (OSTO:SCOL) Headlines

No Headlines